Valneva's Stock Surges 27% in Three Months Ahead of Annual Results
Valneva sees a notable increase this Thursday, March 5, with shares trading at 4.794 euros mid-session, up 2.3% from the previous day's close. This rise comes as the biotech is set to publish its 2025 annual results in less than two weeks. Over three months, the stock performance remains strong with a nearly 27% increase.
Valneva's stock price is currently above all its moving averages, a signal generally interpreted as indicative of a well-established upward trend. The stock is trading at 4.794 euros, which is 13.6% above its 50-day moving average (4.21 euros) and 27.5% above its 200-day moving average (3.76 euros), confirming the strength of the upward movement in recent months. The Relative Strength Index (RSI) is at 58, in a neutral to slightly positive zone, without any overheating signals. The stock still has room before reaching its technical resistance identified at 5.08 euros, which also corresponds to the upper Bollinger band. The monthly volatility, measured at 18.08%, indicates moderate fluctuations for a stock of this profile.
Financial Calendar Enters Crucial Phase
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Valneva's financial calendar is entering a pivotal phase. The company, specializing in vaccines against infectious diseases, will present its 2025 annual results on March 16, just eleven days away. This date is a major event for shareholders, with the stock having risen 46.16% over the year. Beyond this publication, several milestones will mark the coming months: the results for the first quarter of 2026 are expected on May 7, followed by the annual general meeting scheduled for June 1. The semi-annual accounts will be revealed on August 13. This busy sequence will provide increased visibility on the operational and commercial trajectory of the biotech, particularly regarding the ramp-up of its various vaccine programs. Despite a slight decline of 1.44% over the past seven days, the underlying trend remains upward over longer horizons.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
